Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Bibliographic Details
Main Authors:	Xiewei Huang, Yushuai Yu, Shiping Luo, Wenfen Fu, Jie Zhang, Chuangui Song
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Series:	BMC Cancer
Online Access:	https://doi.org/10.1186/s12885-024-11932-4

The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
by: Xiewei Huang, et al.
Published: (2024-01-01)

Editorial: Estrogen receptors in endocrine disorders
by: Tiziana Filardi, et al.
Published: (2023-11-01)

Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer
by: Baha’ Sharaf, et al.
Published: (2024-05-01)

Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
by: Ruiliang Chen, et al.
Published: (2024-12-01)

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer
by: Yubo Wang, et al.
Published: (2023-12-01)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
by: Lorenzo Ferrando, et al.
Published: (2023-01-01)

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
by: Lu-Qi Cao, et al.
Published: (2024-01-01)

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
by: I. Nederlof, et al.
Published: (2022-04-01)

Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients
by: Yuehua Liang, et al.
Published: (2024-01-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
by: Tomás Reinert, et al.
Published: (2017-11-01)

Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy
by: Masahiro Ito, et al.
Published: (2024-02-01)

Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
by: Sarah A. Jeffreys, et al.
Published: (2020-09-01)

Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
by: Yun Wu, et al.
Published: (2024-04-01)

Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer
by: ZHENG Fangchao, et al.
Published: (2022-07-01)

Endocrine Disruptor Degradation by UV/Chlorine and the Impact of Their Removal on Estrogenic Activity and Toxicity
by: Enrico M. Saggioro, et al.
Published: (2019-01-01)

The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients
by: Tomás Reinert, et al.
Published: (2024-06-01)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
by: Hai-long Chen, et al.
Published: (2023-09-01)

Cyclopia extracts act as selective estrogen receptor subtype downregulators in estrogen receptor positive breast cancer cell lines: Comparison to standard of care breast cancer endocrine therapies and a selective estrogen receptor agonist and antagonist
by: Folasade R. Olayoku, et al.
Published: (2023-03-01)

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
by: Yang Yuan, et al.
Published: (2023-06-01)

Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?
by: Merve Keskinkilic, et al.
Published: (2024-06-01)

SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2− breast cancer
by: Kang Li, et al.
Published: (2024-06-01)

Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
by: Jasmine S. Sukumar, et al.
Published: (2024-06-01)

Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis
by: Ping Wu, et al.
Published: (2024-02-01)

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
by: Qiran Wei, et al.
Published: (2023-11-01)

P011 Utility of oncotype in premenopausal women with hormonal receptor (hr) positive her2 negative early breast cancer
by: A. Gasol Cudós, et al.
Published: (2023-03-01)

Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes
by: Fernando Lizcano
Published: (2022-09-01)

Combined chemo-endocrine therapy as a potential new option for HR+/HER2− advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine
by: Xue Wang, et al.
Published: (2023-04-01)

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
by: Rachel Yoder, et al.
Published: (2022-07-01)

Favorable outcome of neoadjuvant endocrine treatment than surgery‐first in female HR‐positive/HER2‐negative breast cancer patients—A NCDB analysis (2010–2016)
by: Peng Xu, et al.
Published: (2024-06-01)

Assessment and Molecular Actions of Endocrine-Disrupting Chemicals That Interfere with Estrogen Receptor Pathways
by: Gwenneg Kerdivel, et al.
Published: (2013-01-01)

Small phenolic compounds as potential endocrine disruptors interacting with estrogen receptor alpha
by: Raul Alva-Gallegos, et al.
Published: (2024-10-01)

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
by: Danilo Giffoni de Mello Morais Mata, et al.
Published: (2022-07-01)

Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2– metastatic breast cancer: a prospective, monocentric study
by: Raffaella Palumbo, et al.
Published: (2024-02-01)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
by: Ami N Shah, et al.
Published: (2020-05-01)

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
by: Jinhao Wang, et al.
Published: (2023-06-01)

Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis
by: Yushuai Yu, et al.
Published: (2023-07-01)

Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer
by: Lei Duan, et al.
Published: (2022-12-01)

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
by: Engel-Nitz NM, et al.
Published: (2023-04-01)

Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Similar Items

Similar Items